IRIDEX (IRIX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $11.6 million, down 10% year-over-year, with a net loss of $1.9 million ($0.12 per share); declines were driven by softness in the retina business and regulatory shipment delays.

• Cyclo G6 glaucoma product revenue grew 3% year-over-year to $3.1 million, with stable demand for consumable probes.

• Cost reduction initiatives and a $3.4 million convertible note improved liquidity and are expected to drive EBITDA breakeven in Q4 2024.

• Strategic review process is ongoing, with leadership transition and active discussions regarding potential transactions.

• Nine-month revenue was $36.0 million, down 8.7% year-over-year, with a net loss of $8.1 million and EPS of $(0.49).

Financial highlights

• Gross profit for Q3 2024 was $4.3 million (37.3% margin), down from $5.6 million (43.7%) in Q3 2023.

• Operating expenses for Q3 2024 were $6.2 million, down from $7.3 million year-over-year.

• Cash and cash equivalents at quarter-end were $3.9 million, including $3.4 million from a convertible note offering.

• Convertible note payable outstanding was $2.7 million, with $1.3 million short-term and $1.4 million long-term.

• Net cash used in operations for nine months was $6.0 million, up from $5.8 million in the prior year.

Outlook and guidance

• Q4 2024 is expected to be EBITDA positive, supported by cost reductions, seasonally strong sales, and new Medicare LCDs effective November 17, 2024.

• Regulatory shipment delays are anticipated to resolve in Q4, aiding revenue recovery.

• Management expects liquidity to be supported through January 2026 by cost savings and recent financing.

• Persistent macroeconomic concerns and capital spending delays in healthcare may continue to impact demand.

• Future capital needs may require additional, potentially dilutive, financing.